Publications & Talks
Our Research / Publications & Talks
Telemedicine to facilitate ALS research.
Gronka S, Walker M, Wuu J, Stanislaw C, Fanos J, Atassi N, Jaffa M, Andersen P, Cudkowicz M, Benatar M (presenter). Telemedicine to facilitate ALS research. Platform presentation at the 21st International Symposium on ALS/MND, Orlando, FL, Dec 11-13, 2010.
Tackling the challenges of ALS from a familial perspective.
Gronka S, Wuu J, Usher S, Polak M, Benatar M (presenter). Tackling the challenges of ALS from a familial perspective. Platform presentation at the 20th International Symposium on ALS/MND, Berlin, Germany, Dec 4-10, 2009.
The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers.
Benatar M (speaker). The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers. NEALS Annual Meeting, Nov 1-3, 2022.
The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers.
Benatar M (speaker). The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers. ALS One 5th Annual ALS Research Symposium. Virtual, Oct 6-7, 2022.
Evolving Paradigms in ALS Therapy Development.
Benatar M (invited speaker). Evolving Paradigms in ALS Therapy Development. 147th Annual Meeting of the American Neurological Association. Chicago, IL, Oct 22-25, 2022.
Rethinking ALS: Prodrome, Biomarkers, Disease Prevention.
Benatar M (keynote speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. The 1st Ontario Clinical ALS Day (OCAD). Toronto, Canada, Oct 21, 2022.
Progress Towards ALS Prevention.
Benatar M (keynote speaker). Progress Towards ALS Prevention. The ALS Association 2022 Virtual Advocacy Conference, June, 2022.
Rethinking ALS: Prodrome, Biomarkers, Disease Prevention.
Benatar M (keynote speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. Expert-in-the-Field speaker at the 10th Annual University of California Irvine Health Neuromuscular Colloquium. Irvine, CA, June, 2022.
Pre-symptomatic mild cognitive and behaviour impairment in ALS-frontotemporal spectrum disorder (ALS-FTSD): A conceptual framework.
McHutchison C (presenter), Abrahams S, Cosentino S, Wuu J, Benatar M. Pre-symptomatic mild cognitive and behaviour impairment in ALS-frontotemporal spectrum disorder (ALS-FTSD): A conceptual framework. European Network to Cure ALS (ENCALS) Annual Meeting. Edinburgh, UK, June 1-3, 2022.
Pinpointing Phenoconversion.
Benatar M (invited speaker). Pinpointing Phenoconversion. European Network to Cure ALS (ENCALS) Annual Meeting. Edinburgh, UK, June 1-3, 2022.
Characterizing pre-symptomatic ALS to identify opportunities for early therapeutic intervention.
Benatar M (invited speaker). Characterizing pre-symptomatic ALS to identify opportunities for early therapeutic intervention. ALS Drug Development Summit. Boston, MA, May 2022.
Rethinking ALS: Prodrome, Biomarkers, Disease Prevention.
Benatar M (invited speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. University College London Queen Square Motor Neuron Disease Center Seminar. London, UK, May 2022.
The ATLAS Study.
Benatar M (invited speaker). The ATLAS Study. NEALS Webinar (virtual), Mar 17, 2022.
Treatment and Prevention: From Genetic to All ALS.
Benatar M (guest speaker). Treatment and Prevention: From Genetic to All ALS. University of Miami Annual ALS Patient Symposium. Virtual, Mar 2022.
Mild Motor Impairment as Prodromal State in ALS.
Benatar M (invited speaker). Mild Motor Impairment as Prodromal State in ALS. 22nd Annual Packard Center Meeting. Baltimore, MD, Feb/Mar 2022.